miRecule has entered into a strategic collaboration with Sanofi with potential future milestone payments of nearly $400 Million

We are thrilled to share that Boutique Venture Partners’ portfolio company, miRecule, Inc., entered into a strategic collaboration and exclusive license agreement with Sanofi to accelerate the discovery, development, and commercialization of a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD)*. miRecule will receive early milestones of a $30 million payment with potential future milestone payments of nearly $400 million, in addition to tiered royalties.Congratulations to Anthony and the entire miRecule team, and we are happy to be an Early Partner. *FSHD is the second most common type of muscular dystrophy – affecting more than one million individuals worldwide with no approved treatments.

https://www.businesswire.com/news/home/20221004005125/en/miRecule-Enters-into-Strategic-Collaboration-with-Sanofi-to-Accelerate-Discovery-and-Development-of-a-Best-in-Class-Antibody-RNA-Conjugate-to-Treat-Facioscapulohumeral-Muscular-Dystrophy-FSHD